Happenings
Viewpoint Project: Future of Healthcare - Innovative solutions
July 27, 2023
Xentria engaged Meitheal in a licensing agreement for the commercialization of XTMAB-16, a clinical-stage anti-TNF monoclonal antibody, to address the unmet medical needs of sarcoidosis patients. XTMAB-16 is currently under clinical investigation.
We are a biotech company building authentic life-sciences partnerships to guide innovative drug and intellectual property development from early concepts through clinical development and towards commercial launch.
Who We AreWe reinvent how life-sciences partnerships can deliver adaptive approaches to ambitious drug innovation for improved patient outcomes.
Guiding Your ConceptOur current pipeline represents how our partnerships guide ambitious developers through challenging drug projects.
View PipelineDiscover how tenacity, expertise, and partnerships built on trust drove Xentria’s development of an Investigational New Drug (IND) candidate aimed to suppress the physiologic response tumor necrosis factor (TNF).
View the JourneyWe are a growing team of resourceful innovators who embrace those with the desire to engage, adapt, serve and solve. Find out how you can apply your talents to advance the development of needed drugs with challenging profiles. The results of your work are noticed, and you can see the difference they make.
Be Part of Our TeamJuly 27, 2023
July 11, 2023
June 27, 2023
May 2023